Cargando…

Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome

Pulmonary fibrosis (PF) is a chronic lung disorder characterized by the presence of scarred and thickened lung tissues. Although the Food and Drug Administration approved two antifibrotic drugs, pirfenidone, and nintedanib, that are currently utilized for treating idiopathic PF (IPF), the clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Yu-Hsin, Chen, I-Chen, Li, Wan-Chun, Hsu, Jong-Hau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341703/
https://www.ncbi.nlm.nih.gov/pubmed/37446052
http://dx.doi.org/10.3390/ijms241310876
_version_ 1785072325010391040
author Tseng, Yu-Hsin
Chen, I-Chen
Li, Wan-Chun
Hsu, Jong-Hau
author_facet Tseng, Yu-Hsin
Chen, I-Chen
Li, Wan-Chun
Hsu, Jong-Hau
author_sort Tseng, Yu-Hsin
collection PubMed
description Pulmonary fibrosis (PF) is a chronic lung disorder characterized by the presence of scarred and thickened lung tissues. Although the Food and Drug Administration approved two antifibrotic drugs, pirfenidone, and nintedanib, that are currently utilized for treating idiopathic PF (IPF), the clinical therapeutic efficacy remains unsatisfactory. It is crucial to develop new drugs or treatment schemes that combine pirfenidone or nintedanib to achieve more effective outcomes for PF patients. Understanding the complex mechanisms underlying PF could potentially facilitate drug discovery. Previous studies have found that the activation of inflammasomes, including nucleotide-binding and oligomerization domain (NOD)-like receptor protein (NLRP)1, NLRP3, NOD-like receptor C4, and absent in melanoma (AIM)2, contributes to lung inflammation and fibrosis. This article aims to summarize the cellular and molecular regulatory cues that contribute to PF with a particular emphasis on the role of AIM2 inflammasome in mediating pathophysiologic events during PF development. The insights gained from this research may pave the way for the development of more effective strategies for the prevention and treatment of PF.
format Online
Article
Text
id pubmed-10341703
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103417032023-07-14 Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome Tseng, Yu-Hsin Chen, I-Chen Li, Wan-Chun Hsu, Jong-Hau Int J Mol Sci Review Pulmonary fibrosis (PF) is a chronic lung disorder characterized by the presence of scarred and thickened lung tissues. Although the Food and Drug Administration approved two antifibrotic drugs, pirfenidone, and nintedanib, that are currently utilized for treating idiopathic PF (IPF), the clinical therapeutic efficacy remains unsatisfactory. It is crucial to develop new drugs or treatment schemes that combine pirfenidone or nintedanib to achieve more effective outcomes for PF patients. Understanding the complex mechanisms underlying PF could potentially facilitate drug discovery. Previous studies have found that the activation of inflammasomes, including nucleotide-binding and oligomerization domain (NOD)-like receptor protein (NLRP)1, NLRP3, NOD-like receptor C4, and absent in melanoma (AIM)2, contributes to lung inflammation and fibrosis. This article aims to summarize the cellular and molecular regulatory cues that contribute to PF with a particular emphasis on the role of AIM2 inflammasome in mediating pathophysiologic events during PF development. The insights gained from this research may pave the way for the development of more effective strategies for the prevention and treatment of PF. MDPI 2023-06-29 /pmc/articles/PMC10341703/ /pubmed/37446052 http://dx.doi.org/10.3390/ijms241310876 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tseng, Yu-Hsin
Chen, I-Chen
Li, Wan-Chun
Hsu, Jong-Hau
Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
title Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
title_full Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
title_fullStr Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
title_full_unstemmed Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
title_short Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
title_sort regulatory cues in pulmonary fibrosis—with emphasis on the aim2 inflammasome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341703/
https://www.ncbi.nlm.nih.gov/pubmed/37446052
http://dx.doi.org/10.3390/ijms241310876
work_keys_str_mv AT tsengyuhsin regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome
AT chenichen regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome
AT liwanchun regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome
AT hsujonghau regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome